The CD19 coCAR enhanced T cell expansion, persistence and anti-tumor function of transgenic survivin-specific TCR T cells targeting leukemia, as well as native EBVSTs targeting lymphomas in vitro and in vivo [200]. Here, BIRC5 is linked to neoplasm.